Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Insulet (NASDAQ:PODD – Get Free Report) had its price target boosted by equities researchers at Citigroup from $310.00 to $355.00 in a note issued to investors on Friday,Benzinga reports. The ...
Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...
Hosted on MSN2d
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds ExpectationsInsulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...
2d
Zacks.com on MSNInsulet (PODD) Q4 Earnings and Revenues Top EstimatesInsulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results